AZN

ASTRAZENECA'S Enhertu Wins EU CHMP Backing in Early Breast Cancer

CHMP recommended Enhertu for adjuvant use in HER2-positive early breast cancer after Phase III trial cut recurrence risk by 53%.

Source: Wikimedia

AstraZeneca (AZN) and partner Daiichi Sankyo said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended Enhertu (trastuzumab deruxtecan) for approval in the European Union as an adjuvant monotherapy for adults with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment.

A utility-scale solar farm of the type planned under the Tadaa and Kainan partnership.

TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project

Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.

A natural gas wellhead of the kind found across Pennsylvania's Marcellus shale.

ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M

Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.

Palisade Bio is developing an oral prodrug aimed at inflammatory bowel disease.

FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease

Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.

PDS Biotechnology is seeking a partner to fund Phase 3 development of its HPV16-targeted immunotherapy PDS0101.

PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival

VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.

Read more

TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project

ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M

FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease

PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival